J 2017

Locally advanced breast cancer in elderly patients

HORNOVA, Jana, Zbyněk BORTLÍČEK, Petra MÁJKOVÁ, Jitka ABRAHAMOVA, Drahomira KORDIKOVA et. al.

Basic information

Original name

Locally advanced breast cancer in elderly patients

Authors

HORNOVA, Jana (203 Czech Republic), Zbyněk BORTLÍČEK (203 Czech Republic, guarantor, belonging to the institution), Petra MÁJKOVÁ (203 Czech Republic, belonging to the institution), Jitka ABRAHAMOVA (203 Czech Republic), Drahomira KORDIKOVA (203 Czech Republic), Zuzana DONATOVA (203 Czech Republic), Martin KUPEC (203 Czech Republic), Ludmila BOUBLIKOVA (203 Czech Republic), Josef DVORAK (203 Czech Republic), Radek ZAPLETAL (203 Czech Republic) and Tomas BUCHLER (203 Czech Republic)

Edition

Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Czech Republic, Olomouc, Palacký University, 2017, 1213-8118

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.087

RIV identification code

RIV/00216224:14110/17:00097429

Organization unit

Faculty of Medicine

UT WoS

000406522700014

Keywords in English

breast cancer; Charlson score; elderly; retrospective analysis; survival

Tags

Tags

International impact, Reviewed
Změněno: 20/3/2018 14:04, Soňa Böhmová

Abstract

V originále

Background. Although locally advanced breast cancer (LABC) is more common in the elderly population, there is little data on the clinical characteristics and survival of these patients. The aim of the present study was to compare different factors affecting survival in elderly patients with LABC. Methods. Retrospective analysis was carried out on a cohort of 80 patients aged 70 to 96 years, diagnosed with LABC defined as T3 N1, T4 N0, any N2 or N3, and M0. The prognostic impact of selected clinical parameters including age, comorbidities, tumour grade, HER2 status, tumour stage, local therapies, and systemic treatments was studied. Results. The median age of the patients was 79 years. The majority (n=53; 66%) had at least one significant comorbidity according to the Charlson score evaluation. The median overall survival was 50.6 months. As expected, hormonal therapy was the dominant mode of systemic treatment, but 24% also received at least one line of chemotherapy. Local therapies including surgery and/or radiotherapy were applied in 58% of patients. Conclusions. The diagnosis of LABC in the elderly is associated with poor prognosis. Age and serious comorbidities were negative prognostic factors.